However, more recently, results from a phase I/II clinical trial reported that none of the IDH-mutant glioma patients treated with azacytidine in combination with mutant IDH1 inhibitor, olutasidenib, had a clinical response to treatment and all patients progressed within 10 weeks (Table 2; NCT03684811). This evidence concerns the gene IDH1 and central nervous system cancer.